Current view of the management of patients with endometrial hyperplasia: A review
| Autor: | Aznar S. Khachatryan, Yulia E. Dobrokhotova, Irina Yu. Il'ina, Sergey N. Kazantsev |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Гинекология, Vol 26, Iss 1, Pp 11-15 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2079-5696 2079-5831 20795696 |
| DOI: | 10.26442/20795696.2024.1.202654 |
| Popis: | Endometrial hyperplasia (EH) is a spectrum of morphological changes in the endometrium characterized by the proliferation of glands and an increase in the gland-stromal ratio. The relevance of this disease is due to its high prevalence (10–55%). The clinical significance of EH is related to the increased risk of endometrioid cancer. One of the leading causes of EH is absolute or relative hyperestrogenism and progesterone deficiency that does not eliminate the proliferative effect of estrogens. The risk group for EH includes women with early menarche, late menopause, infertility, anovulation, polycystic ovary syndrome, obesity, type 2 diabetes mellitus, hypertension, Lynch syndrome, estrogen-producing ovarian tumors, as well as those receiving estrogen monotherapy or tamoxifen. Most leading experts believe that therapy should include surgery followed by drug therapy aimed at eliminating risk factors to reduce the risk of EH recurrence. Despite numerous research findings demonstrating the benefits of a particular treatment modality and the consequent presence of these modalities in clinical guidelines, the potential benefits of alternative therapies are still being discussed. This issue requires further study and the selection of optimal treatment regimens for patients with EH. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|